Other TLR2 agonists or their modified forms, lipopeptides also have been reported to be useful for the cancer treatment,10, 11, 12, 13, 14, 15, 16 which further suggests the potential of TLR2 agonist as effective enhancers for cancer immunotherapies.17 However, the current known TLR2 agonists, lipopeptides or their derivatives, are having limitations because of the difficulties in synthesis, susceptibility to hydrolysis, as well as in eliciting inflammatory cytokine storm. This evidence concerns the gene TLR2 and cancer.